|Articles|June 20, 2019

June 2019 Digital Edition

Pipeline watch: we look closely at drugs in phase 2, phase 3 or recently approved for basal cell carcinoma and melanoma. Plus, treating patients with autism, and the physician's impact on regulations and pay.

 

Download the digital edition

 

Subscribe to Dermatology Times!   Print & Digital / eNewsletter

 

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME